B+
Bull case
25%
Probability
Target price
$3.60
Analysis reference price unavailable
Analysis 2026-06-20 · RankAlpha Sentiment Codex
OVID
Ovid TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The constructive case is that Ovid now has two live clinical value drivers: OV329 has generated supportive dose-escalation safety/PK data for patient studies, and OV4071 has entered Phase 1, while the larger cash balance extends operating flexibility [#SEC-8K-2026-03-18] [#PR-EARNINGS-2026-05-12].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Clinical readouts for OV329 and OV4071 remain the core value drivers, so any weak safety, PK, exposure, or proof-of-concept signal could materially pressure the stock.
Momentum
93
Value
41
Sentiment
52
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.40 · Bull $3.60 · Bear $1.40Analysis 2026-06-20; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-08 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-20 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-08
Investment thesis
As of 2026-09-08
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-08. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $6.14
Why
Momentum93 · Δ7d -
Value41 · Δ7d -0.0
Sentiment52 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Clinical readouts for OV329 and OV4071 remain the core value drivers, so any weak safety, PK, exposure, or proof-of-concept signal could materially pressure the stock.
- • Despite stronger liquidity, Ovid is still loss-making and likely dependent on capital markets or partnerships over time; runway reduces near-term pressure but does not remove dilution risk [#PR-EARNINGS-2026-05-12].
- • The bearish case is that this remains a low-coverage, pre-revenue biotech with limited third-party validation in the packet, no recent independent news flow, and a negative deterministic prior; if OV329 or OV4071 data slip or disappoint, the equity can re-rate quickly lower.
Catalyst clock
2026-09-30
OV4071 Phase 1 human data progression
Lead driver: Sentiment · See AI snapshot
Momentum
93
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
52
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 92.8 / Value 41.2 / Sentiment 51.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-06-20. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$2.40
Analysis reference price unavailable
Analysis 2026-06-20 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$1.40
Analysis reference price unavailable
Analysis 2026-06-20 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$564.41M
Beta
0.26
Shares Out
195.3M
P/E (TTM) · Derived
-12.2
P/S (TTM)
32.69
P/FCF (TTM) · Derived
-5.78
Rev YoY
-88.3%
EPS YoY
+15.3%
Gross Margin
+92.9%
Op Margin
-585.2%
Net Debt
-$56.22M
Current Ratio
12.39
As of 2026-09-08 • Updated nightlySource: Internal modelMethods & Data